The Optomed Polaris and Optomed Halo are now available in the U.S.
SAN FRANCISCO, June 7, 2021 (Newswire.com) – Optomed USA, Inc., a wholly owned subsidiary of Optomed Plc, a Finnish medical technology company, is expanding its product line to include two tabletop fundus imaging cameras now available to the U.S. market. “We have received a great deal of interest in our flagship Optomed Aurora handheld fundus camera, however, in some instances the need for a tabletop solution is obvious, and we want to be able to offer a compelling solution to serve these customers,” said Jean-Christophe, President & CEO of Optomed USA, Inc.
The Optomed Polaris provides eye care professionals with a fully automatic, non-mydriatic fundus camera. This stationary device has a small footprint, requires minimal training, and provides sharp quality 45° images of the retina. The Optomed Polaris helps improve the lives of patients and assists eye care providers with the early detection of various retinal diseases.
Optomed Polaris product photo – https://optosf.optomed.com/f/a3eb0360e8cc4492b19b/
The Optomed Halo is a fully automatic non-mydriatic retinal camera. Its light weight and small footprint allows for easy transporting. Social distancing is easily possible with the Optomed Halo because the controlling computer can locate up to 25 feet away from the camera or behind a glass wall. This makes image taking very safe for the patient and eye care professional.
Optomed Halo product photo – https://optosf.optomed.com/f/831113af2b234d7da0a3/
“The addition of the Optomed Polaris and Optomed Halo tabletop cameras to the already popular handheld Optomed Aurora camera option gives eye care professional a variety of cameras to aid in early detection and appropriate treatment to better serve their patients.” The Optomed Polaris and Optomed Halo are available online at www.optomed.com/us/buy-now or contacting your Optomed representative.
Optomed Plc is a Finnish medical technology company and one of the leading providers of handheld fundus cameras worldwide. Optomed Plc combines handheld screening devices with software and optional artificial intelligence integration with the aim to transform the diagnostic process of blinding eye-diseases such as rapidly increasing diabetic retinopathy. In its business, Optomed Plc focuses on eye-screening devices and software solutions-related R&D in Finland, and sales through different channels in over 60 countries. Optomed Plc has an extensive portfolio of over 50 international patents protecting the technology.
This press release contains ” forward-looking statements” relating to future events. These statements may be identified by words such as ” may,” “could,” “expects,” “intends,” “anticipates,” “plans,” “believes,” “aims,” “estimates,” or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Optomed Plc and its affiliates (including Optomed USA, Inc.) may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Optomed USA, Inc. and its affiliates, including, without limitation, the global spread of COVID-19, or the Coronavirus, and the various restrictions deriving therefrom. In addition, Optomed Plc and its affiliates (including Optomed USA, Inc.) rely, and expect to continue to rely, on third parties to conduct certain activities, and if these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines (including as a result of the effect of the Coronavirus), Optomed Plc and its affiliates (including Optomed USA, Inc.) may experience significant delays in the conduct of their activities. Optomed Plc and its affiliates (including Optomed USA, Inc.) disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.
Source: Optomed USA, Inc.